Search Result

Results for "

anti-hepatitis C virus activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (3) HCV (15) Apoptosis (2) Cyclophilin (1) DNA/RNA Synthesis (1) Drug Metabolite (4) Endogenous Metabolite (3) Glycosidase (2) HIV (1) Isotope-Labeled Compounds (1) Nucleoside Antimetabolite/Analog (1) PI3K (1) PI4K (1)
By Research Areas:	Infection (18)
Oligonucleotides:	Nucleosides and their Analogs (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: HCV HBV Influenza Virus Dengue Virus Virus Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12559

Alisporivir Maximum Cited Publications 15 Publications Verification Debio-025; DEB-025	Cyclophilin HCV	Infection
Alisporivir (Debio-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.

HY-15005B

Sofosbuvir impurity C	Drug Metabolite	Others
Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0727

Sofosbuvir impurity E	Drug Metabolite	Others
Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0719

Sofosbuvir impurity B	Drug Metabolite	Others
Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0723

Sofosbuvir impurity D	Drug Metabolite	Others
Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I1196

Sofosbuvir impurity L	HCV	Infection
Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-15005C

Sofosbuvir impurity A	HCV	Infection
Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-W103964

HCV-IN-47	HCV	Infection
HCV-IN-47 (Compound (R)-1) shows anti-hepatitis C virus (HCV) activity with an EC₅₀ value of 0.032 μM. HCV-IN-47 is promising for research of hepatitis C virus pathogenesis, and host-virus interaction .

HY-W753521

Deleobuvir sodium BI 207127 sodium	Endogenous Metabolite	Infection
Deleobuvir sodium (BI 207127 sodium) is a non-nucleoside hepatitis C virus NS5B polymerase inhibitor with anti-hepatitis C virus activity .

HY-148171

L-2'-Fd4C	HIV HBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human *immunodeficiency virus* (HIV) and anti-hepatitis B virus (HBV)** activity .

HY-I0515

Sofosbuvir impurity K	HCV	Infection
Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0512

Sofosbuvir impurity I	HCV	Infection
Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0513

Sofosbuvir impurity N	HCV	Others
Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0938

Sofosbuvir impurity H	HCV	Infection
Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0975

Sofosbuvir impurity J	HCV	Infection
Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0735

Sofosbuvir impurity M	HCV	Infection
Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0406

Sofosbuvir impurity F	HCV	Infection
Sofosbuvir impurity F, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-I0408

Sofosbuvir impurity G	HCV	Others
Sofosbuvir impurity G, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

HY-15005S

Sofosbuvir-13C,d3 PSI-7977-¹³C,d₃; GS-7977-¹³C,d₃	Isotope-Labeled Compounds HCV	Infection
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15005S1

Sofosbuvir-d6 PSI-7977-d₆; GS-7977-d₆	HCV	Infection
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15005A

PSI-7976	HCV	Infection
PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-N0058

4,5-Dicaffeoylquinic acid 5+ Cited Publications Isochlorogenic acid C	HBV Endogenous Metabolite Apoptosis Glycosidase	Infection
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .

HY-N0058R

4,5-Dicaffeoylquinic acid (Standard)	HBV Endogenous Metabolite Apoptosis Glycosidase	Infection
4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .

HY-100603A

(S)-GSK-F1	PI3K PI4K	Infection
(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC₅₀ of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	334 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 334 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

334 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 334 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area